Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy

Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy.

Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news